{"id":"lodosyn","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Acute disease of cardiovascular system","Acute nephropathy","Angle-closure glaucoma","Cardiovascular event risk","Cataract surgery","Conduction disorder of the heart","Depressive disorder","Diabetes mellitus","Diarrhea","Disease of liver","Disorder of lung","Drug-induced psychosis","Duodenal ulcer disease","Dyskinesia","Gastric ulcer","Gastrointestinal hemorrhage","Hallucinations","Hepatic failure","Intraoperative floppy iris syndrome","Kidney disease","Malignant melanoma","Myocardial infarction","Obstruction of bile duct","Open-angle glaucoma","Orthostatic hypotension","Peptic ulcer","Psychoneurotic personality disorder","Psychotic disorder","Retention of urine","Seizure disorder","Suicidal thoughts"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT06180720","NCT01437293","NCT00218023","NCT00272688","NCT01840423","NCT01515410","NCT00360568","NCT02169479","NCT04244058","NCT00203164","NCT04493320","NCT01351168","NCT00456586","NCT02706977","NCT02116790","NCT06236230","NCT03761030","NCT07444892","NCT01171313","NCT02799381","NCT01103011","NCT00460954","NCT03023059","NCT00537017","NCT02764125","NCT04590612","NCT00947037","NCT00253084","NCT00199420","NCT00203177","NCT02633007","NCT05976737","NCT00918177","NCT00199407","NCT00143026","NCT06219915","NCT01190813","NCT05094050","NCT04469959","NCT00693862","NCT00139880","NCT02611713","NCT01617135","NCT06626152","NCT02812394","NCT00099268","NCT02633839","NCT02480803","NCT02615873","NCT05083260"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Lodosyn","companyId":"university-of-miami","ecosystem":[],"mechanism":{"target":"Lysine-specific demethylase 4E, Aromatic-L-amino-acid decarboxylase, Tyrosine-protein kinase Fyn","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"University of Miami","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Lodosyn","indications":{"approved":[{"name":"Parkinson's disease","diseaseId":"parkinson's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Parkinsonism","diseaseId":"parkinsonism","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Postencephalitic parkinsonism","diseaseId":"postencephalitic-parkinsonism","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06180720","phase":"Phase 1","title":"Single-Center, Open, Randomized, Single-Dose, Completely Repeated Crossover Bioequivalence Study to Evaluate the Effects of the Test/Reference Preparation, Entacapone,Levodopa and Carbidopa Tablets (I","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","isPivotal":false,"enrollment":36,"indication":"Healthy","completionDate":"2024-11-20"},{"nctId":"NCT01437293","phase":"Phase 1","title":"Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE)","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","isPivotal":false,"enrollment":15,"indication":"Cocaine Abuse","completionDate":"2012-04"},{"nctId":"NCT00218023","phase":"Phase 2","title":"Screening Medications for Cocaine Cessation and Relapse Prevention","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","isPivotal":false,"enrollment":101,"indication":"Cocaine Abuse, Cocaine-Related Disorders","completionDate":"2012-04"},{"nctId":"NCT00272688","phase":"Phase 4","title":"Continuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic Evaluation","status":"COMPLETED","sponsor":"University Hospital, Akershus","isPivotal":false,"enrollment":10,"indication":"Parkinson Disease","completionDate":"2009-05"},{"nctId":"NCT01840423","phase":"Phase 1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-104: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre Firs","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","isPivotal":false,"enrollment":101,"indication":"Healthy","completionDate":"2014-12"},{"nctId":"NCT01515410","phase":"Phase 2","title":"A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patient","status":"COMPLETED","sponsor":"Depomed","isPivotal":false,"enrollment":34,"indication":"Parkinson's Disease, Motor Fluctuations","completionDate":"2012-10"},{"nctId":"NCT00360568","phase":"Phase 3","title":"Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","isPivotal":true,"enrollment":62,"indication":"Dyskinesias, Parkinson's Disease","completionDate":"2012-10"},{"nctId":"NCT02169479","phase":"Phase 1","title":"Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa: a Doubleblind, Randomized, F","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","isPivotal":false,"enrollment":16,"indication":"Parkinson's Disease (PD)","completionDate":"2008-12"},{"nctId":"NCT04244058","phase":"EARLY/Phase 1","title":"Evaluation of Pharmacologically-induced Changes in Excitatory Glutamatergic Neurotransmission of Severe TBI Patients","status":"SUSPENDED","sponsor":"Weill Medical College of Cornell University","isPivotal":false,"enrollment":30,"indication":"Disorder of Consciousness, Traumatic Brain Injury","completionDate":"2023-06-30"},{"nctId":"NCT00203164","phase":"Phase 3","title":"A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated ","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","isPivotal":true,"enrollment":254,"indication":"Parkinson's Disease","completionDate":"2006-09"},{"nctId":"NCT04493320","phase":"Phase 4","title":"1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","isPivotal":false,"enrollment":5,"indication":"Depression, Cognitive Impairment","completionDate":"2021-10-27"},{"nctId":"NCT01351168","phase":"Phase 2","title":"A Randomized, Controlled, Double-Blind, Cross-over Study of Zolpidem for Patients With Parkinson's Disease","status":"WITHDRAWN","sponsor":"Rush University Medical Center","isPivotal":false,"enrollment":0,"indication":"Parkinson's Disease","completionDate":""},{"nctId":"NCT00456586","phase":"Phase 2","title":"A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/Day KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Le","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","isPivotal":false,"enrollment":180,"indication":"Parkinson's Disease","completionDate":"2003-06"},{"nctId":"NCT02706977","phase":"Phase 1","title":"The Effect of Dopamine on Diabetic Retinopathy","status":"COMPLETED","sponsor":"Emory University","isPivotal":false,"enrollment":60,"indication":"Diabetes","completionDate":"2019-08-15"},{"nctId":"NCT02116790","phase":"Phase 2","title":"Study of the Efficacy of Co-administration of an NSAID With a Dopamine Agonist in the Alleviation of Acute Cutaneous Inflammatory Pain in Healthy Subjects","status":"WITHDRAWN","sponsor":"Northwestern University","isPivotal":false,"enrollment":0,"indication":"Acute Pain","completionDate":"2015-01"},{"nctId":"NCT06236230","phase":"Phase 4","title":"Basic and Clinical Studies of Levodopa/Carbidopa/Entacapone in the Treatment of Early Parkinson's Disease","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","isPivotal":false,"enrollment":60,"indication":"Parkinson Disease","completionDate":"2024-12-31"},{"nctId":"NCT03761030","phase":"Phase 4","title":"Targeting Dopaminergic Mechanisms of Slowing to Improve Late Life Depression","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","isPivotal":false,"enrollment":51,"indication":"Major Depressive Disorder, Dysthymia","completionDate":"2021-09-08"},{"nctId":"NCT07444892","phase":"Phase 2","title":"Levodopa for Diabetic Retinopathy","status":"COMPLETED","sponsor":"Emory University","isPivotal":false,"enrollment":230,"indication":"Diabetic Retinopathy","completionDate":"2025-11-17"},{"nctId":"NCT01171313","phase":"Phase 2","title":"A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations","status":"COMPLETED","sponsor":"XenoPort, Inc.","isPivotal":false,"enrollment":35,"indication":"Parkinson's Disease","completionDate":"2011-12"},{"nctId":"NCT02799381","phase":"Phase 3","title":"An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Adv","status":"COMPLETED","sponsor":"AbbVie","isPivotal":true,"enrollment":63,"indication":"Parkinson's Disease (PD)","completionDate":"2019-09-19"},{"nctId":"NCT01103011","phase":"Phase 1","title":"A Phase I, Single Center, Blinded, Controlled Study Evaluating Safety, Tolerability and Pharmacokinetic Profile of Levodopa Following Repeated Administration of Oral Levodopa/Carbidopa and Continuousl","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","isPivotal":false,"enrollment":8,"indication":"Parkinson's Disease","completionDate":"2010-10"},{"nctId":"NCT00460954","phase":"N/A","title":"An Open Label, Multiple-Dose Study ot Determine the Plasma Levodopa Profiles of Sinemet® CR (Carbidopa/Levodopa) at 4 Daily Dose Levels in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":20,"indication":"Parkinson's Disease","completionDate":"2007-08"},{"nctId":"NCT03023059","phase":"Phase 2","title":"Proof of Concept and Dose Ranging Study of Carbidopa-levodopa in Neovascular AMD","status":"COMPLETED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","isPivotal":false,"enrollment":35,"indication":"Age-related Macular Degeneration","completionDate":"2020-05-04"},{"nctId":"NCT00537017","phase":"Phase 2","title":"A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 (Preladenant) 5 mg BID (P05175)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":140,"indication":"Parkinson Disease, Neurodegenerative Diseases","completionDate":"2009-11-19"},{"nctId":"NCT02764125","phase":"Phase 2","title":"Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-o","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","isPivotal":false,"enrollment":84,"indication":"Parkinson's Disease","completionDate":"2018-03-27"},{"nctId":"NCT04590612","phase":"NA","title":"The Effects of Mood Symptoms Treatment on Quality of Life and Motor Function in de Novo Parkinson's Disease Patients","status":"UNKNOWN","sponsor":"Western University, Canada","isPivotal":false,"enrollment":30,"indication":"Parkinson Disease, Depression","completionDate":"2022-01"},{"nctId":"NCT00947037","phase":"Phase 2","title":"An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects","status":"WITHDRAWN","sponsor":"Intec Pharma Ltd.","isPivotal":false,"enrollment":0,"indication":"Parkinson's Disease","completionDate":""},{"nctId":"NCT00253084","phase":"Phase 2","title":"A Randomized, Double-Blind, Cross-Over Study to Compare IPX054 to Carbidopa-Levodopa Immediate-Release Tablets in Subjects With Parkinson's Disease","status":"COMPLETED","sponsor":"Impax Laboratories, LLC","isPivotal":false,"enrollment":12,"indication":"Parkinson's Disease","completionDate":"2007-12"},{"nctId":"NCT00199420","phase":"Phase 3","title":"A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of 10, 20 and 40 mg/d Oral Dose of KW-6002 (Istradefylline) a","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","isPivotal":true,"enrollment":580,"indication":"Parkinson's Disease","completionDate":"2005-12"},{"nctId":"NCT00203177","phase":"Phase 3","title":"A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated ","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","isPivotal":true,"enrollment":254,"indication":"Parkinson's Disease","completionDate":""},{"nctId":"NCT02633007","phase":"Phase 1","title":"A Phase 1 Study of the Safety and Pharmacokinetics (PK) of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma","status":"COMPLETED","sponsor":"Acorda Therapeutics","isPivotal":false,"enrollment":25,"indication":"Asthma","completionDate":"2016-05"},{"nctId":"NCT05976737","phase":"Phase 1","title":"Single-Center, Open, Randomized, Single-Dose, Completely Repeated Crossover Bioequivalence Study to Evaluate the Effects of the Test/Reference Preparation, Entacapone,Levodopa and Carbidopa Tablets (I","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","isPivotal":false,"enrollment":68,"indication":"Healthy","completionDate":"2024-07-12"},{"nctId":"NCT00918177","phase":"Phase 2","title":"Dual Release Gastric Retentive AP09004, Vs. Active Control; a Pharmacokinetic/Pharmacodynamic, Comparative, Safety Evaluation in Parkinson's Patients","status":"COMPLETED","sponsor":"Intec Pharma Ltd.","isPivotal":false,"enrollment":72,"indication":"Parkinson's Disease","completionDate":""},{"nctId":"NCT00199407","phase":"Phase 3","title":"A 12-week, Double Blind, Placebo-controlled, Randomized, Parallel Group, Multicenter, Fixed Dose Study to Evaluate the Efficacy and Safety of a 20 mg/d Oral Dose of KW-6002 (Istradefylline) as Treatme","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","isPivotal":true,"enrollment":230,"indication":"Parkinson's Disease","completionDate":"2006-01"},{"nctId":"NCT00143026","phase":"Phase 4","title":"Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease.","status":"COMPLETED","sponsor":"Novartis","isPivotal":false,"enrollment":184,"indication":"Parkinson's Disease","completionDate":"2006-06"},{"nctId":"NCT06219915","phase":"Phase 1","title":"Neurobiological Drivers of Mobility Resilience: The Dopaminergic System","status":"COMPLETED","sponsor":"University of Michigan","isPivotal":false,"enrollment":13,"indication":"Parkinsonian Signs in Older Persons","completionDate":"2024-05-30"},{"nctId":"NCT01190813","phase":"Phase 3","title":"A Randomized Trial of Levodopa as Treatment for Residual Amblyopia (ATS 17)","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","isPivotal":true,"enrollment":139,"indication":"Amblyopia","completionDate":"2014-04"},{"nctId":"NCT05094050","phase":"Phase 1","title":"Parkinson's Disease: A Comparative Study of Levodopa and Carbidopa Bioavailability Following Foslevodopa/Foscarbidopa Infusion at Different Subcutaneous Sites in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"AbbVie","isPivotal":false,"enrollment":16,"indication":"Parkinson's Disease","completionDate":"2023-03-17"},{"nctId":"NCT04469959","phase":"Phase 2","title":"Dopaminergic Dysfunction in Late-Life Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","isPivotal":false,"enrollment":100,"indication":"Late Life Depression, Cognitive Decline","completionDate":"2026-07-30"},{"nctId":"NCT00693862","phase":"Phase 1","title":"Levodopa Concentration Profile After Repeated Doses of Stalevo","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","isPivotal":false,"enrollment":19,"indication":"Pharmacokinetics","completionDate":"2008-05"},{"nctId":"NCT00139880","phase":"Phase 3","title":"A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":true,"enrollment":0,"indication":"Parkinson's Disease","completionDate":"2005-08"},{"nctId":"NCT02611713","phase":"N/A","title":"DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)","status":"COMPLETED","sponsor":"AbbVie","isPivotal":false,"enrollment":213,"indication":"Advanced Parkinson's Disease","completionDate":"2020-12-24"},{"nctId":"NCT01617135","phase":"Phase 2","title":"A Randomized, Placebo-Controlled, Phase 2 Study of the Safety, Pharmacokinetics and Pharmacodynamics of CVT-310 (Levodopa Inhalation Powder) in Patients With Parkinson's Disease and Motor Response Flu","status":"COMPLETED","sponsor":"Acorda Therapeutics","isPivotal":false,"enrollment":25,"indication":"Idiopathic Parkinson's Disease","completionDate":"2012-12"},{"nctId":"NCT06626152","phase":"Phase 2","title":"Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial","status":"RECRUITING","sponsor":"University of British Columbia","isPivotal":false,"enrollment":50,"indication":"Major Depressive Disorder","completionDate":"2026-05-30"},{"nctId":"NCT02812394","phase":"Phase 1","title":"A Phase 1 Single Dose Pharmacokinetic Bridging Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets","status":"COMPLETED","sponsor":"Acorda Therapeutics","isPivotal":false,"enrollment":24,"indication":"Parkinson Disease","completionDate":"2016-09"},{"nctId":"NCT00099268","phase":"Phase 3","title":"A Long Term, Double-blind, Randomized, Parallel-group, Carbidopa/Levodopa Controlled, Multi-center Study to Evaluate the Effect of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Re","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"enrollment":747,"indication":"Parkinson's Disease","completionDate":"2008-11"},{"nctId":"NCT02633839","phase":"Phase 1","title":"A Phase 1 Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults","status":"COMPLETED","sponsor":"Acorda Therapeutics","isPivotal":false,"enrollment":60,"indication":"Smoking","completionDate":"2016-06"},{"nctId":"NCT02480803","phase":"Phase 4","title":"Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","isPivotal":false,"enrollment":51,"indication":"Parkinson's Disease","completionDate":"2024-01-26"},{"nctId":"NCT02615873","phase":"Phase 3","title":"An Open-Label,Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004","status":"UNKNOWN","sponsor":"Intec Pharma Ltd.","isPivotal":true,"enrollment":460,"indication":"Parkinson's Disease","completionDate":"2019-12"},{"nctId":"NCT05083260","phase":"Phase 1","title":"A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's Disease (PD) Participants Treated With Carbidopa/Levodopa and NE3107","status":"COMPLETED","sponsor":"BioVie Inc.","isPivotal":false,"enrollment":46,"indication":"Parkinson Disease","completionDate":"2023-01-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}